Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by bluemoons20on Mar 26, 2024 10:41pm
128 Views
Post# 35954505

discussion

discussionI  would imagine he does not have the money to  buy  Replicel  out.  Just saying , to get me to vote  yes  would  be a  $2  per share buyout  right  now.

As to the  transaction  Seems to say 8%  of  any  sale  or income from the assets  plus an additional 3%  from a sale of the assets.  This would go into the  'delisted'  Replicell  for division and distribution to the  shareholders.   And  those  shareholders  would include  Andrew.  So he would  get his 8%  too.

As for transparency, there will be none in his company   and I  am not sure  what  would be available for Replicel  - once delisted  is it still a  publically traded company??  Likely not,  So I guess you  just  look through  your mail  and one day there will be a cheque  in it for $ 2.48  for your royalty on one of the asset sales!!???

All Andrew needs  is to  get  say $6 million  for sale of the patents  or the injector and he is good!!


GLTA
<< Previous
Bullboard Posts
Next >>